Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies to treat central nervous system disorders. The company's lead product candidate, KarXT, is a proprietary oral modulator of muscarinic receptors that are located both in the central nervous system and various peripheral tissues. KarXT is being developed for the treatment of schizophrenia and other neuropsychiatric disorders. The company also has a pipeline of other product candidates in preclinical development, including KarXT for the treatment of dementia-related psychosis, as well as programs targeting pain, sleep, and other disorders. Karuna Therapeutics was founded in 2009 and is headquartered in Boston, Massachusetts.
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies to treat central nervous system disorders. The company's lead product candidate, KarXT, is a proprietary oral modulator of muscarinic receptors that are located both in the central nervous system and various peripheral tissues. KarXT is being developed for the treatment of schizophrenia and other neuropsychiatric disorders. The company also has a pipeline of other product candidates in preclinical development, including KarXT for the treatment of dementia-related psychosis, as well as programs targeting pain, sleep, and other disorders. Karuna Therapeutics was founded in 2009 and is headquartered in Boston, Massachusetts.